Corporate Action8 Jul 2026, 12:58 pm
Suven Life Sciences Allots 1.85 Cr Shares on Warrant Conversion
AI Summary
Suven Life Sciences Ltd announced the allotment of 1,85,70,133 equity shares on a preferential basis following the conversion of fully paid warrants. The shares were issued at a price of ₹134 per share to non-promoter entities, raising a total of ₹248.84 crore. This issuance increases the company's paid-up equity share capital. The Board of Directors also approved the re-appointment of Dr. Vajja Sambasiva Rao as an Independent Director for a second term and the incorporation of a wholly-owned subsidiary in Singapore. The Board meeting was held on July 8, 2026.
Key Highlights
- 1.85 crore equity shares allotted upon warrant conversion.
- ₹248.84 crore raised via preferential allotment.
- Share capital increased post-allotment.
- Independent Director re-appointed for five years.
- Wholly-owned subsidiary to be incorporated in Singapore.
Price Impact
More from SUVEN